CINECA IRIS Institutional Research Information System

TAMPELLINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.405
EU - Europa 3.697
AS - Asia 2.489
SA - Sud America 78
OC - Oceania 50
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 15
Totale 11.771
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.278
CN - Cina 1.355
IT - Italia 702
DE - Germania 493
SE - Svezia 417
IE - Irlanda 383
FR - Francia 364
SG - Singapore 288
GB - Regno Unito 244
FI - Finlandia 230
KR - Corea 226
UA - Ucraina 219
JP - Giappone 182
PL - Polonia 170
AT - Austria 115
CA - Canada 100
VN - Vietnam 91
IN - India 71
DK - Danimarca 69
ES - Italia 61
TW - Taiwan 54
TH - Thailandia 52
NL - Olanda 48
ID - Indonesia 43
AU - Australia 42
BE - Belgio 38
BR - Brasile 38
HK - Hong Kong 35
TR - Turchia 31
CH - Svizzera 27
AR - Argentina 24
CZ - Repubblica Ceca 19
MX - Messico 18
RU - Federazione Russa 18
GR - Grecia 17
RO - Romania 15
SN - Senegal 14
HR - Croazia 10
IR - Iran 10
PH - Filippine 10
EU - Europa 9
PT - Portogallo 9
LB - Libano 8
NZ - Nuova Zelanda 8
MO - Macao, regione amministrativa speciale della Cina 7
NO - Norvegia 7
RS - Serbia 7
AP - ???statistics.table.value.countryCode.AP??? 6
CL - Cile 6
DZ - Algeria 6
IL - Israele 6
PE - Perù 5
RE - Reunion 5
UZ - Uzbekistan 5
HU - Ungheria 4
SA - Arabia Saudita 4
SV - El Salvador 4
CO - Colombia 3
IQ - Iraq 3
MY - Malesia 3
PK - Pakistan 3
TN - Tunisia 3
CR - Costa Rica 2
EG - Egitto 2
LT - Lituania 2
LV - Lettonia 2
MA - Marocco 2
MM - Myanmar 2
MU - Mauritius 2
SI - Slovenia 2
ZA - Sudafrica 2
BG - Bulgaria 1
BS - Bahamas 1
BY - Bielorussia 1
ET - Etiopia 1
IS - Islanda 1
MT - Malta 1
NI - Nicaragua 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
Totale 11.771
Salva come PNG Salva come JPEG
Città #
Beijing 668
Chandler 439
Fairfield 430
Dublin 379
Houston 367
Ann Arbor 318
Ashburn 214
Wilmington 207
Woodbridge 207
Villeurbanne 203
Singapore 202
Seattle 165
Princeton 163
Jacksonville 158
Torino 143
Cambridge 142
Warsaw 140
Pisa 137
Medford 126
Nyköping 126
Hangzhou 124
Redwood City 121
Dearborn 110
Vienna 109
Guangzhou 100
Fremont 97
Shanghai 88
Dong Ket 69
Boston 66
Milan 57
Tokyo 43
Munich 40
Jakarta 38
Nanjing 38
Toronto 37
Seoul 35
Taipei 35
Boardman 34
London 33
New York 33
Santa Clara 33
San Diego 26
Shenyang 26
Brussels 25
Chengdu 22
Duncan 22
Jinan 21
Bangkok 20
Ottawa 20
Verona 19
Phoenix 18
Wuhan 18
Rome 17
Norwalk 16
Silver Spring 16
Falls Church 15
Helsinki 15
Buenos Aires 14
Mountain View 14
Nürnberg 14
Brno 13
Central District 12
Detroit 12
Kunming 12
Newbury Park 12
Salt Lake City 12
Zhengzhou 12
Barcelona 10
Berlin 10
Cleveland 10
Istanbul 10
Madrid 10
Paris 10
Polska 10
Turin 10
Chicago 9
Copenhagen 9
Düsseldorf 9
Florence 9
Fuzhou 9
Hefei 9
Nanchang 9
Toulouse 9
Hyderabad 8
Lachine 8
Pittsburgh 8
Pune 8
Amsterdam 7
Bari 7
Changchun 7
Frankfurt am Main 7
Hanawada 7
Hong Kong 7
Manchester 7
New Delhi 7
Piemonte 7
Winnipeg 7
Ankara 6
Guadalajara 6
Los Angeles 6
Totale 6.989
Salva come PNG Salva come JPEG
Nome #
Novel anti-angiogenic therapeutic strategies in colorectal cancer 754
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? 660
Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit 488
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. 269
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. 267
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study 261
Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology: Beyond Citation Counts 237
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease 225
Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin-5-Fluorouracil-Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963). 216
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 213
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: A case report and review of the literature 194
The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. 192
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer 184
Pharmacoeconomic aspects of FOLFIRI or FOLFOX regimens administered with a fully ambulatory pump compared to the day hospital setting. 181
Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study 173
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen 173
Role of surgical resection in colorectal lung metastases: analysis of 137 patients. 172
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis 169
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy 168
Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. 162
Novel investigational therapies for treating biliary tract carcinoma 155
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. 152
Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed 146
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. 145
CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS 145
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 145
Enzalutamide in prostate cancer after chemotherapy. 142
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer 134
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. 121
Stage IB malignant thymoma in a Lynch syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil 120
THE ROLE OF HEMOGLOBIN LEVEL IN PREDICTING THE RESPONSE TO FIRST-LINE CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER (ACC) PATIENTS 119
Chirurgia delle metastasi polmonari da carcinoma colo-rettale: una serie di 171 pazienti. 118
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 115
Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions 110
Is it Possible to avoid rh-TSH test in Patients with Differentiated Thyroid Carcinoma by Using the Association between Ablation and Suppressive Thyroglobulin? 107
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY 105
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma 98
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. 96
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. 96
Intermittent everolimus administration for malignant insulinoma 94
Circadian rhythm of breakthrough cancer pain. 93
Melatonin and human cancer. 92
Cronochemioterapia dei tumori del colon-retto avanzati 92
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: A case report 92
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. 91
Randomized trial of TAS-102 for refractory metastatic colorectal cancer 89
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 88
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients 86
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients 83
Aggiornamenti in Cronochemioterapia 81
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 77
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome 73
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 72
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. 72
Circadian variation of breakthrough pain in cancer patients. 71
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. 70
THE ONSET OF SKELETAL COMPLICATIONS IN HORMONEREFRACTORY PROSTATE CANCER PATIENTS IS NOT INFLUENCEDBY THE DURATION OF ANDROGEN DEPRIVATION THERAPY 70
Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects 70
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. 69
PALLIATIVE CARE PATIENTS HAD A CIRCADIAN RHYTHMICITY IN THEIR BREAKTHROUGH PAIN (BTP) EPISODES 68
INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY 67
Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. 66
TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC) 65
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy 64
The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) 64
Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy 64
Role of surgical resection in colorectal lung metastases: analysis of 137 patients 63
Il trattamento dell'ascite neoplastica: obiettivi e criteri di valutazione 63
Prognostic factors in advanced colorectal carcinoma: A multifactorial analysis 63
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: The PRESSING case-control study 63
Chronomodulated delivery schedule of Oxaliplatin (OHP), 5-Fluorouracil and Folinic Acid (FFL4/10) allows to increase significantly dose intensity rate of OHP based schedule: 2 years experience in gastrointestinal cancers 63
Cronochemioterapia dei tumori del colon retto metastatici 61
MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression 61
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, cremona, Italy (2010) 59
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. 58
NATURAL HISTORY OF MALIGNANT BONE DISEASE IN COLORECTAL CANCER: FINAL RESULTS OF A LARGE ITALIAN "BONE METASTASES" SURVEY 58
Survival of lung surgery patients with pulmonary metastases from colonic neoplasms 57
Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: Case report and literature review 56
The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy 56
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. 54
GENDER-DEPENDENT OPTIMAL SCHEDULING OFCANCER CHRONOTHERAPEUTICS 54
Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey 52
In Reply 52
Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation 51
Predictive factors for skeletal complications in prostate cancer patients with hormone refractory disease 51
A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors? 51
Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. 49
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients. 47
Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. 47
Thymidine phosphorylase: The unforeseen driver in colorectal cancer treatment? 46
The prognostic value of some biological parameters (c-ras, p53, Ki67) in patients undergoing radical cystectomy for bladder carcinoma. 45
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load 45
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up 45
Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. 45
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease 43
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. 42
Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients 42
Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. 42
Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy 41
Seminal monolateral nerve-sparing radical prostatectomy in selected patients 40
Totale 11.575
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.990
article - articoli 0
book - libri 0
conference - conferenze 4.934
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.718 0 0 0 276 159 267 292 180 187 130 120 107
2020/20211.233 140 85 92 104 104 70 102 59 111 114 84 168
2021/20221.413 98 70 88 186 53 41 104 85 47 76 288 277
2022/20231.654 213 114 44 125 155 448 150 76 156 26 98 49
2023/2024823 110 112 48 44 80 69 52 41 16 58 64 129
2024/2025399 54 196 115 34 0 0 0 0 0 0 0 0
Totale 12.161